Hannah Valantine sold $207k of BBIO
director at BridgeBio Pharma, Inc.. 4,707 shares at an average of $44.05, traded Jun 26, 2025, filed Jun 30, 2025.
Score components
- +15RoleDirector
- +12Trade size$207k at market
- +10Share of holdings soldSold 48% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-091762, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 26, 2025 | SOpen-market sale Common Stock | -876 | $44.11 | $39k | 9,007 | Jun 30, 2025 |
| Jun 26, 2025 | SOpen-market sale Common Stock | -1,542 | $44.01 | $68k | 7,465 | Jun 30, 2025 |
| Jun 26, 2025 | SOpen-market sale Common Stockindirect: By Spouse | -398 | $44.13 | $18k | 2,289 | Jun 30, 2025 |
| Jun 26, 2025 | SOpen-market sale Common Stockindirect: By Spouse | -1,891 | $44.03 | $83k | 398 | Jun 30, 2025 |
Related signals
Other insiders at BridgeBio Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $691k 10,000 shares | -2% | |
| 28Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $2.2M 30,011 shares | -12% | |
| 14Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $149k 2,000 shares | -2% | |
| 43Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $5.9M 80,000 shares | -10% | |
| 50Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $1.7M 26,156 shares | -10% | |
| 25Weak | BridgeBio Pharma, Inc. | Randal W. Scott director | $666k 10,000 shares | -46% | |
| 75Notable | BridgeBio Pharma, Inc. | Andrew Lo director | $6.3M 95,599 shares | -175% | |
| 42Moderate | BridgeBio Pharma, Inc. | Thomas Trimarchi President and CFO | $1.1M 16,934 shares | -4% | |
| 60Notable | BridgeBio Pharma, Inc. | Hannah Valantine director | $1.7M 25,484 shares | -77% | |
| 45Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $5.0M 80,000 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.